24 May 2013
Keywords: merck, kgaa, licenses, rights, apitope, ms, drug
Article | 19 January 2009
Germany's Merck KGaA has signed an R&D and commercialization agreement with the UK's Apitope Technology, a wholly-owned subsidiary
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 January 2009
23 May 2013
© 2013 thepharmaletter.com